companies / atamyo-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Evry, France | |
| industry | unknown | |
| stage | null |
Atamyo brings to patients with musculoskeletal diseases a new generation of high-performing gene therapies with enhanced safety and efficacy. This name conveys the spirit of the company in its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient. Our Pipeline At Atamyo, we use our expertise in ge.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-09-01 | grant | 2,700,0002.7M | null | ○ |
WordPress 6.7.5, Apache HTTP Server 2.4.38, Lightbox, scrollreveal 6.7.5, Slick, Debian, Contact Form 7 5.6.3, WP Fastest Cache, PHP, MySQL, apache 2.4.38, jquery 3.3.1
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |